William Blair Has Negative Estimate for Biogen Q2 Earnings

Biogen Inc. (NASDAQ:BIIB - Free Report) - Stock analysts at William Blair lowered their Q2 2025 earnings per share (EPS) estimates for Biogen in a report released on Wednesday, April 23rd. William Blair analyst M. Minter now expects that the biotechnology company will earn $4.10 per share for the quarter, down from their previous estimate of $4.20. William Blair has a "Outperform" rating on the stock. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. William Blair also issued estimates for Biogen's Q4 2025 earnings at $3.83 EPS and FY2026 earnings at $14.64 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, topping analysts' consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%.

BIIB has been the subject of a number of other research reports. Truist Financial dropped their price target on Biogen from $210.00 to $199.00 and set a "buy" rating on the stock in a research note on Tuesday. BMO Capital Markets cut their target price on Biogen from $156.00 to $139.00 and set a "market perform" rating on the stock in a research note on Thursday, February 13th. Morgan Stanley cut their price objective on shares of Biogen from $157.00 to $152.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 9th. The Goldman Sachs Group decreased their target price on shares of Biogen from $219.00 to $197.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Finally, Royal Bank of Canada increased their price objective on shares of Biogen from $221.00 to $225.00 and gave the stock an "outperform" rating in a research note on Tuesday, April 22nd. Twenty analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $201.93.

Biogen Stock Up 0.8 %

Shares of BIIB stock traded up $0.91 during trading hours on Monday, hitting $121.08. 1,525,356 shares of the company were exchanged, compared to its average volume of 1,346,724. Biogen has a 52 week low of $110.04 and a 52 week high of $238.00. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.27. The business has a 50 day moving average of $131.78 and a two-hundred day moving average of $148.18. The company has a market capitalization of $17.72 billion, a PE ratio of 10.82, a PEG ratio of 1.51 and a beta of 0.06.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BIIB. Inspire Trust Co. N.A. lifted its holdings in Biogen by 58.5% in the third quarter. Inspire Trust Co. N.A. now owns 10,900 shares of the biotechnology company's stock valued at $2,113,000 after buying an additional 4,025 shares during the period. Assenagon Asset Management S.A. boosted its stake in Biogen by 0.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 43,460 shares of the biotechnology company's stock worth $6,646,000 after acquiring an additional 111 shares in the last quarter. Amundi grew its holdings in Biogen by 35.6% in the fourth quarter. Amundi now owns 1,216,990 shares of the biotechnology company's stock worth $183,461,000 after purchasing an additional 319,478 shares during the period. Centre Asset Management LLC increased its position in Biogen by 7.7% in the 4th quarter. Centre Asset Management LLC now owns 51,530 shares of the biotechnology company's stock valued at $7,880,000 after buying an additional 3,698 shares in the last quarter. Finally, Integrated Quantitative Investments LLC acquired a new position in Biogen during the 4th quarter worth approximately $407,000. Institutional investors own 87.93% of the company's stock.

Insiders Place Their Bets

In related news, Director Stephen A. Sherwin sold 8,760 shares of Biogen stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the transaction, the director now directly owns 11,318 shares of the company's stock, valued at $1,697,926.36. The trade was a 43.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.16% of the company's stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.